This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Anti-Viral Drugs Market

Encouraging Healthcare Policies and Rising Prevalence of Viral Diseases Spurs Demand for Anti-Viral Drugs across the Globe

Anti-Viral Drugs Market by Product Type, End User & Region - Forecast 2022 - 2032

Anti-Viral Drugs Market Snapshot (2022-2032)

[298 Pages Report] The global anti-viral drugs market is expected to be valued at US$ 59,596.8 Million in 2022. The induction of the generic version of antiviral medicines and rising awareness about the availability of various vaccines for viral infections is affecting the growth throughout the forecast period. The overall demand for Anti-Viral Drugs is projected to grow at a CAGR of 3.9% between 2022 and 2032, totaling around US$ 87,675.36 Million by 2032.

Data Points

Key Statistics

Anti-Viral Drugs Market Value 2022

US$ 59,596.8 Million

Anti-Viral Drugs Market Projected Value (2032)

US$ 87,675.36 Million

Anti-Viral Drugs Market CAGR (2022-2032)

3.9%

Anti-viral drugs are medicines that are used especially for treating viral infections. Most anti-viral drugs are used for particular viral infections, similar to antibiotics, while a broad-spectrum anti-viral drug is effective against a varied range of viruses. Antiviral drugs do not kill their target pathogen, instead, they inhibit the development of those viruses.

The global anti-viral drugs market is projected to register a moderate growth rate in the pharmaceutical market and which is anticipated to increase due to a rise in awareness level, an increase in the diseased population, and the introduction of new drugs with improved efficacy.

Some major patents are reaching their expiry during the forecast periods, such as Combivir, Sustiva, Tenofovir, Tamiflu, Relenza, and Telbivudine. The patent expiries of these blockbuster drugs are expected to trigger generic competition in the antivirals therapeutics market, which will make the market more competitive.

The late-stage pipeline drugs are expected to enter the market, which will positively impact the market. Most antivirals are considered comparatively harmless to the host and therefore are used to treat infections. They are different from viricides, which are not used for medication but can destroy or deactivate virus particles, either outside or inside the body. The anti-viral drugs are used in the treatment of patients suffering from herpes viruses, HIV, influenza A, and B viruses, and hepatitis B and C viruses.

Customize this Report

Let us know your requirement to get
100% FREE customization

Anti-Viral Drugs Demand Analysis (2016 to 2021) Vs Market Outlook (2022 to 2032)

The global demand for Anti-Viral Drugs is projected to increase at a CAGR of 3.9% during the forecast period between 2022 and 2032, reaching a total of US$ 87.67 Billion in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 3.4~%.

During the historic outlook, the biggest driver of the overall anti-viral drugs market was Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) therapeutic sales which accounted for more than half the share of the market in 2021. According to WHO, in 2021, several patients living with HIV are 38.4 million, and 650k people acquired the disease in the same year.

Nearly four out of five people were freshly put on treatment in sub-Saharan Africa. In 21 African countries with a high burden of HIV, two out of three people in need are receiving treatment, and two out of three positive pregnant women are receiving antiretroviral drugs to prevent HIV transmission to their infants. The introduction of solid R&D activities, newer and advanced treatments, and formulations, such as vaccines, and combination therapy are projected to fuel the market growth of anti-viral drugs over the forecast period.

Which Drivers underpin Anti-Viral Drugs Industry Expansion?

The increasing commonness of viral infections such as HIV, Herpes, Influenza, and others are expected to upsurge the demand for antiviral medicines throughout the forecast period. For instance, according to UNAIDS, in 2020, more than 37 billion individuals were living with HIV across the globe. Out of these, approximately 1.5 billion new people acquired HIV infection in 2020. Overall, the COVID-19 pandemic has pointedly accelerated the market growth in 2021 whereas, a negative impact of the pandemic has been detected for other applications of antiviral drugs.

Owing to the solid R&D activities, newer and advanced treatments and formulations, such as vaccines, combination therapy, and others, are being introduced in the market, and the demand is anticipated to upsurge. Hence, strong R&D is one of the crucial factors in the anti-viral drugs market growth

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Which Factors are limiting the Growth of the Anti-Viral Drugs Market?

Several factors hampering the market expansion of Anti-Viral Drugs include high risk of failure, high cost of R&D and therapy, and government austerity. However, swelling usage of natural products and the high cost of developing drugs are the key challenges faced by the market.

Region-wise Insights

Will North America Hold a Significant Position in the Global Anti-Viral Drugs Market?

In terms of market contribution, North America acquires the largest share in the revenue collection across the globe, accounting for 38.7% share in 2022. As per the recent analysis by Future Market Insights, the region is anticipated to maintain its dominance during the assessment period 2022-2032. The United States and Canada are estimated to be the largest shareholders in the regional revenue generation.

The market decline can be attributed to the loss of market exclusivity of patented drugs, mounting vaccination rates against viral infections, and government initiatives to minimize the prevalence of viral infections.

For instance, the U.S. government is responsible for several measures including funding and grants in infectious diseases programs and encouraging the R&D activities of innovative therapies to manage viral infections.

How Will Growth of the European Anti-Viral Drugs Market unfold?

Based on the geographies, European is the second-largest region, acquiring a 14.9% share in the Anti-Viral Drugs market. During the forecast period, the region is estimated to witness moderate growth, backed by soaring investments in the development of new drugs and therapies. This market growth is also attributed to the easy approval and promising healthcare policies by several governments.

In April 2022, European Medicines Agency, the European Union’s drug regulator signed off on emergency usage of Merck’s Covid antiviral pill for adults who get tested positive as it prepares to decide on full approval by the year’s end.

In July 2021, GSK and Vir announced a Joint Procurement Agreement (JPA) with the European Commission to supply up to 220,000 doses of sotrovimab. Following the grant of the marketing authorization in the EU, Member States participating in the JPA can now order sotrovimab to support their pandemic responses. These initiatives are likely to fuel the market growth of Anti-Viral Drugs in the coming years.

How the APAC region is Bolstering the Demand for Anti-Viral Drugs?

In the Asia Pacific, the market for antiviral drugs is anticipated to witness the fastest growth rate throughout the forecast period. The exponential growth of the market can be attributed to the rising prevalence and treatment rate of viral infections, emerging healthcare infrastructure in the region, and growing awareness among people regarding infectious diseases.

Besides, the strong presence of generic pharmaceutical manufacturing companies in India, China, and other South Asian countries and the rising geriatric population in the region are some of the principal driving factors of the segment.

The introduction of new and innovative strategies in the emerging economies is also likely to boost the demand for Anti-Viral Drugs over the coming decade.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Category-wise Insights

By Application, Which Anti-Viral Drugs Category Will Remain Prominent?

The global anti-viral drugs market is segmented based on product type and end-user. The HIV segment captures the majority share in terms of market revenue generation. and held the largest revenue share of 44.1% in 2021. The segment is projected to observe the fastest growth rate over the forecast period. The rising prevalence of HIV infection associated with a high treatment rate, availability of branded drugs, and government initiatives to upsurge the treatment rate is projected to stimulate the market at a higher growth rate.

For instance, in 2019, the U.S. government introduced the Ending the HIV Epidemic (EHE) plan to end the HIV epidemic in the country by 2032. The initiative seeks to decrease HIV infections and enhance the diagnosis and treatment rate in the U.S. Furthermore, the existence of strong pipeline drugs for HIV infection will also fuel market growth throughout the conjecture period.

The hepatitis segment held the second-largest revenue share in 2021. Escalating vaccination against hepatitis A and B is affecting the growth adversely. Besides, the occurrence of the COVID-19 pandemic has significantly augmented the growth of the other segment in 2020.

The Start-Up Ecosystem: How key Players are Opening Frontiers for Future Growth?

  • Founded in 2010, New American Therapeutics is a US-based specialty pharmaceutical company. The company acquires, markets, and develops therapeutic products for infectious diseases. It develops Denavir, an antiviral topical drug for the treatment of recurrent herpes labialis in adults and children 12 years of age and older. Denavir was acquired from Novartis in 2010
  • Founded in 2009, Adaptive Biotechnologies is a U.S based provider of clinical diagnostics, and drug discovery for immune diseases. The company's immune profiling sequencing technology immunoSEQ enables characterization of the immune system, helping scientists & clinicians in research and drug development. The company also offers clonoSEQ for monitoring Minimal Residual Disease (MRD) in blood-based cancers. Also, develops cell therapies, vaccines, and antibody molecules for infectious diseases.

Competitive Landscape: What are the Leading Players in the Anti-Viral Drugs Market Up to?

  • In May 2022, Cipla Limited, in partnership with Genes2Me Pvt. Ltd., announced the commercialization of the 'RT-Direct' multiplex COVID-19 RT PCR Test kit in India. Cipla is increasing its diagnostics portfolio in an attempt to take more innovative and innovative solutions to the market.
  • In May 2022, Abbott reached an agreement with the Food and Drug Administration on Monday to reopen the company's manufacturing plant in Michigan to help ease a nationwide shortage of baby formula, after the facility was closed due to bacterial contamination.
  • In March 2022, Scripps Research, non-profit research and technology, drug discovery organization, and AbbVie Inc. established a strategic collaboration to investigate novel, immediate antiviral treatments for COVID-19.

Report Scope

Report Attribute

Details

Growth Rate

CAGR of 3.9% from 2022-2032

Market Value in 2022

US$ 59.59 Billion

Market Value in 2032

US$ 87.67 Billion

Base Year for Estimation

2021

Historical Data

2017-2021

Forecast Period

2022-2032

Quantitative Units

Revenue in US$ Million and CAGR from 2022-2032

Report Coverage

Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis

Segments Covered

  • Product type
  • End-user
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • The Asia Pacific
  • The Middle East and Africa

Key Countries Profiled

  • The U.S
  • Canada
  • Brazil
  • Mexico
  • Germany
  • The U.K
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • Malaysia
  • Singapore
  • Australia
  • New Zealand
  • GCC
  • South Africa
  • Israel

Key Companies Profiled

  • Roche
  • Gilead
  • GlaxoSmithKline
  • Bristol-Myers-Squibb
  • Abbott
  • AstraZeneca
  • Cipla
  • Bayer AG
  • Johnson & Johnson
  • Merck & Co
  • AbbVie
  • Aurobindo Pharma
  • Dr. Reddy’s Laboratories Ltd.

Key Segments Covered in the Anti-Viral Drugs Industry Analysis

Anti-Viral Drugs Market by Product type:

  • Hepatitis-C antivirals
  • HIV antivirals
  • Herpes antivirals
  • Hepatitis-B antivirals
  • Influenza antivirals
  • Others (Pneumonia, Flu, etc.)

Anti-Viral Drugs Market by End-user:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers

Anti-Viral Drugs Market by Region:

  • North America Anti-Viral Drugs Market
  • Latin America Anti-Viral Drugs Market
  • Europe Anti-Viral Drugs Market
  • Asia Pacific Anti-Viral Drugs Market
  • The Middle East & Africa Anti-Viral Drugs Market

Frequently Asked Questions

As of 2022, the Anti-Viral Drugs market is slated to reach a valuation of US$ 59.59 Billion .

From 2022-2032, sales of Anti-Viral Drugs are expected to grow at a 3.9% CAGR.

By 2032, Future Market Insights expects the Anti-Viral Drugs market to reach US$ 87.67 Billion.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Anti-Viral Drugs Market Analysis 2016-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2016-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Anti-Viral Drugs Market Analysis 2016-2021 and Forecast 2022-2032, By Product Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Product Type, 2016-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Product Type, 2022-2032

        5.3.1. Hepatitis-C Antivirals

        5.3.2. HIV Antivirals

        5.3.3. Herpes Antivirals

        5.3.4. Hepatitis-B Antivirals

        5.3.5. Influenza Antivirals

        5.3.6. Others (Pneumonia, Flu, etc.)

    5.4. Y-o-Y Growth Trend Analysis By Product Type, 2016-2021

    5.5. Absolute $ Opportunity Analysis By Product Type, 2022-2032

6. Global Anti-Viral Drugs Market Analysis 2016-2021 and Forecast 2022-2032, By End User

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By End User, 2016-2021

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User, 2022-2032

        6.3.1. Hospitals

        6.3.2. Clinics

        6.3.3. Ambulatory Surgical Centers

    6.4. Y-o-Y Growth Trend Analysis By End User, 2016-2021

    6.5. Absolute $ Opportunity Analysis By End User, 2022-2032

7. Global Anti-Viral Drugs Market Analysis 2016-2021 and Forecast 2022-2032, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2016-2021

    7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. Asia Pacific

        7.3.5. MEA

    7.4. Market Attractiveness Analysis By Region

8. North America Anti-Viral Drugs Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        8.2.1. By Country

            8.2.1.1. US

            8.2.1.2. Canada

        8.2.2. By Product Type

        8.2.3. By End User

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Product Type

        8.3.3. By End User

    8.4. Key Takeaways

9. Latin America Anti-Viral Drugs Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Product Type

        9.2.3. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Product Type

        9.3.3. By End User

    9.4. Key Takeaways

10. Europe Anti-Viral Drugs Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. U.K.

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Product Type

        10.2.3. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Product Type

        10.3.3. By End User

    10.4. Key Takeaways

11. Asia Pacific Anti-Viral Drugs Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. China

            11.2.1.2. Japan

            11.2.1.3. South Korea

            11.2.1.4. Rest of Asia Pacific

        11.2.2. By Product Type

        11.2.3. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Product Type

        11.3.3. By End User

    11.4. Key Takeaways

12. MEA Anti-Viral Drugs Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. GCC Countries

            12.2.1.2. South Africa

            12.2.1.3. Israel

            12.2.1.4. Rest of MEA

        12.2.2. By Product Type

        12.2.3. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Product Type

        12.3.3. By End User

    12.4. Key Takeaways

13. Key Countries Anti-Viral Drugs Market Analysis

    13.1. US

        13.1.1. Pricing Analysis

        13.1.2. Market Share Analysis, 2021

            13.1.2.1. By Product Type

            13.1.2.2. By End User

    13.2. Canada

        13.2.1. Pricing Analysis

        13.2.2. Market Share Analysis, 2021

            13.2.2.1. By Product Type

            13.2.2.2. By End User

    13.3. Brazil

        13.3.1. Pricing Analysis

        13.3.2. Market Share Analysis, 2021

            13.3.2.1. By Product Type

            13.3.2.2. By End User

    13.4. Mexico

        13.4.1. Pricing Analysis

        13.4.2. Market Share Analysis, 2021

            13.4.2.1. By Product Type

            13.4.2.2. By End User

    13.5. Germany

        13.5.1. Pricing Analysis

        13.5.2. Market Share Analysis, 2021

            13.5.2.1. By Product Type

            13.5.2.2. By End User

    13.6. U.K.

        13.6.1. Pricing Analysis

        13.6.2. Market Share Analysis, 2021

            13.6.2.1. By Product Type

            13.6.2.2. By End User

    13.7. France

        13.7.1. Pricing Analysis

        13.7.2. Market Share Analysis, 2021

            13.7.2.1. By Product Type

            13.7.2.2. By End User

    13.8. Spain

        13.8.1. Pricing Analysis

        13.8.2. Market Share Analysis, 2021

            13.8.2.1. By Product Type

            13.8.2.2. By End User

    13.9. Italy

        13.9.1. Pricing Analysis

        13.9.2. Market Share Analysis, 2021

            13.9.2.1. By Product Type

            13.9.2.2. By End User

    13.10. China

        13.10.1. Pricing Analysis

        13.10.2. Market Share Analysis, 2021

            13.10.2.1. By Product Type

            13.10.2.2. By End User

    13.11. Japan

        13.11.1. Pricing Analysis

        13.11.2. Market Share Analysis, 2021

            13.11.2.1. By Product Type

            13.11.2.2. By End User

    13.12. South Korea

        13.12.1. Pricing Analysis

        13.12.2. Market Share Analysis, 2021

            13.12.2.1. By Product Type

            13.12.2.2. By End User

    13.13. GCC Countries

        13.13.1. Pricing Analysis

        13.13.2. Market Share Analysis, 2021

            13.13.2.1. By Product Type

            13.13.2.2. By End User

    13.14. South Africa

        13.14.1. Pricing Analysis

        13.14.2. Market Share Analysis, 2021

            13.14.2.1. By Product Type

            13.14.2.2. By End User

    13.15. Israel

        13.15.1. Pricing Analysis

        13.15.2. Market Share Analysis, 2021

            13.15.2.1. By Product Type

            13.15.2.2. By End User

14. Market Structure Analysis

    14.1. Competition Dashboard

    14.2. Competition Benchmarking

    14.3. Market Share Analysis of Top Players

        14.3.1. By Regional

        14.3.2. By Product Type

        14.3.3. By End User

15. Competition Analysis

    15.1. Competition Deep Dive

        15.1.1. Roche

            15.1.1.1. Overview

            15.1.1.2. Product Portfolio

            15.1.1.3. Profitability by Market Segments

            15.1.1.4. Sales Footprint

            15.1.1.5. Strategy Overview

                15.1.1.5.1. Marketing Strategy

        15.1.2. Gilead

            15.1.2.1. Overview

            15.1.2.2. Product Portfolio

            15.1.2.3. Profitability by Market Segments

            15.1.2.4. Sales Footprint

            15.1.2.5. Strategy Overview

                15.1.2.5.1. Marketing Strategy

        15.1.3. GlaxoSmithKline

            15.1.3.1. Overview

            15.1.3.2. Product Portfolio

            15.1.3.3. Profitability by Market Segments

            15.1.3.4. Sales Footprint

            15.1.3.5. Strategy Overview

                15.1.3.5.1. Marketing Strategy

        15.1.4. Bristol-Myers Squibb

            15.1.4.1. Overview

            15.1.4.2. Product Portfolio

            15.1.4.3. Profitability by Market Segments

            15.1.4.4. Sales Footprint

            15.1.4.5. Strategy Overview

                15.1.4.5.1. Marketing Strategy

        15.1.5. Abbott

            15.1.5.1. Overview

            15.1.5.2. Product Portfolio

            15.1.5.3. Profitability by Market Segments

            15.1.5.4. Sales Footprint

            15.1.5.5. Strategy Overview

                15.1.5.5.1. Marketing Strategy

        15.1.6. AstraZeneca

            15.1.6.1. Overview

            15.1.6.2. Product Portfolio

            15.1.6.3. Profitability by Market Segments

            15.1.6.4. Sales Footprint

            15.1.6.5. Strategy Overview

                15.1.6.5.1. Marketing Strategy

        15.1.7. Cipla

            15.1.7.1. Overview

            15.1.7.2. Product Portfolio

            15.1.7.3. Profitability by Market Segments

            15.1.7.4. Sales Footprint

            15.1.7.5. Strategy Overview

                15.1.7.5.1. Marketing Strategy

        15.1.8. Bayer AG

            15.1.8.1. Overview

            15.1.8.2. Product Portfolio

            15.1.8.3. Profitability by Market Segments

            15.1.8.4. Sales Footprint

            15.1.8.5. Strategy Overview

                15.1.8.5.1. Marketing Strategy

        15.1.9. Johnson & Johnson

            15.1.9.1. Overview

            15.1.9.2. Product Portfolio

            15.1.9.3. Profitability by Market Segments

            15.1.9.4. Sales Footprint

            15.1.9.5. Strategy Overview

                15.1.9.5.1. Marketing Strategy

        15.1.10. Merck & Co

            15.1.10.1. Overview

            15.1.10.2. Product Portfolio

            15.1.10.3. Profitability by Market Segments

            15.1.10.4. Sales Footprint

            15.1.10.5. Strategy Overview

                15.1.10.5.1. Marketing Strategy

        15.1.11. AbbVie

            15.1.11.1. Overview

            15.1.11.2. Product Portfolio

            15.1.11.3. Profitability by Market Segments

            15.1.11.4. Sales Footprint

            15.1.11.5. Strategy Overview

                15.1.11.5.1. Marketing Strategy

        15.1.12. Aurobindo Pharma

            15.1.12.1. Overview

            15.1.12.2. Product Portfolio

            15.1.12.3. Profitability by Market Segments

            15.1.12.4. Sales Footprint

            15.1.12.5. Strategy Overview

                15.1.12.5.1. Marketing Strategy

        15.1.13. Dr. Reddy’s Laboratories Ltd

            15.1.13.1. Overview

            15.1.13.2. Product Portfolio

            15.1.13.3. Profitability by Market Segments

            15.1.13.4. Sales Footprint

            15.1.13.5. Strategy Overview

                15.1.13.5.1. Marketing Strategy

16. Assumptions & Acronyms Used

17. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Anti-Viral Drugs Market Value (US$ Mn) Forecast by Region, 2016-2032

Table 2: Global Anti-Viral Drugs Market Value (US$ Mn) Forecast by Product Type, 2016-2032

Table 3: Global Anti-Viral Drugs Market Value (US$ Mn) Forecast by End User, 2016-2032

Table 4: North America Anti-Viral Drugs Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 5: North America Anti-Viral Drugs Market Value (US$ Mn) Forecast by Product Type, 2016-2032

Table 6: North America Anti-Viral Drugs Market Value (US$ Mn) Forecast by End User, 2016-2032

Table 7: Latin America Anti-Viral Drugs Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 8: Latin America Anti-Viral Drugs Market Value (US$ Mn) Forecast by Product Type, 2016-2032

Table 9: Latin America Anti-Viral Drugs Market Value (US$ Mn) Forecast by End User, 2016-2032

Table 10: Europe Anti-Viral Drugs Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 11: Europe Anti-Viral Drugs Market Value (US$ Mn) Forecast by Product Type, 2016-2032

Table 12: Europe Anti-Viral Drugs Market Value (US$ Mn) Forecast by End User, 2016-2032

Table 13: Asia Pacific Anti-Viral Drugs Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 14: Asia Pacific Anti-Viral Drugs Market Value (US$ Mn) Forecast by Product Type, 2016-2032

Table 15: Asia Pacific Anti-Viral Drugs Market Value (US$ Mn) Forecast by End User, 2016-2032

Table 16: MEA Anti-Viral Drugs Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 17: MEA Anti-Viral Drugs Market Value (US$ Mn) Forecast by Product Type, 2016-2032

Table 18: MEA Anti-Viral Drugs Market Value (US$ Mn) Forecast by End User, 2016-2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Anti-Viral Drugs Market Value (US$ Mn) by Product Type, 2022-2032

Figure 2: Global Anti-Viral Drugs Market Value (US$ Mn) by End User, 2022-2032

Figure 3: Global Anti-Viral Drugs Market Value (US$ Mn) by Region, 2022-2032

Figure 4: Global Anti-Viral Drugs Market Value (US$ Mn) Analysis by Region, 2016-2032

Figure 5: Global Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 6: Global Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 7: Global Anti-Viral Drugs Market Value (US$ Mn) Analysis by Product Type, 2016-2032

Figure 8: Global Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Product Type, 2022-2032

Figure 9: Global Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Product Type, 2022-2032

Figure 10: Global Anti-Viral Drugs Market Value (US$ Mn) Analysis by End User, 2016-2032

Figure 11: Global Anti-Viral Drugs Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 12: Global Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 13: Global Anti-Viral Drugs Market Attractiveness by Product Type, 2022-2032

Figure 14: Global Anti-Viral Drugs Market Attractiveness by End User, 2022-2032

Figure 15: Global Anti-Viral Drugs Market Attractiveness by Region, 2022-2032

Figure 16: North America Anti-Viral Drugs Market Value (US$ Mn) by Product Type, 2022-2032

Figure 17: North America Anti-Viral Drugs Market Value (US$ Mn) by End User, 2022-2032

Figure 18: North America Anti-Viral Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 19: North America Anti-Viral Drugs Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 20: North America Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 21: North America Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 22: North America Anti-Viral Drugs Market Value (US$ Mn) Analysis by Product Type, 2016-2032

Figure 23: North America Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Product Type, 2022-2032

Figure 24: North America Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Product Type, 2022-2032

Figure 25: North America Anti-Viral Drugs Market Value (US$ Mn) Analysis by End User, 2016-2032

Figure 26: North America Anti-Viral Drugs Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 27: North America Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 28: North America Anti-Viral Drugs Market Attractiveness by Product Type, 2022-2032

Figure 29: North America Anti-Viral Drugs Market Attractiveness by End User, 2022-2032

Figure 30: North America Anti-Viral Drugs Market Attractiveness by Country, 2022-2032

Figure 31: Latin America Anti-Viral Drugs Market Value (US$ Mn) by Product Type, 2022-2032

Figure 32: Latin America Anti-Viral Drugs Market Value (US$ Mn) by End User, 2022-2032

Figure 33: Latin America Anti-Viral Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 34: Latin America Anti-Viral Drugs Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 35: Latin America Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 36: Latin America Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 37: Latin America Anti-Viral Drugs Market Value (US$ Mn) Analysis by Product Type, 2016-2032

Figure 38: Latin America Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Product Type, 2022-2032

Figure 39: Latin America Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Product Type, 2022-2032

Figure 40: Latin America Anti-Viral Drugs Market Value (US$ Mn) Analysis by End User, 2016-2032

Figure 41: Latin America Anti-Viral Drugs Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 42: Latin America Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 43: Latin America Anti-Viral Drugs Market Attractiveness by Product Type, 2022-2032

Figure 44: Latin America Anti-Viral Drugs Market Attractiveness by End User, 2022-2032

Figure 45: Latin America Anti-Viral Drugs Market Attractiveness by Country, 2022-2032

Figure 46: Europe Anti-Viral Drugs Market Value (US$ Mn) by Product Type, 2022-2032

Figure 47: Europe Anti-Viral Drugs Market Value (US$ Mn) by End User, 2022-2032

Figure 48: Europe Anti-Viral Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 49: Europe Anti-Viral Drugs Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 50: Europe Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 51: Europe Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 52: Europe Anti-Viral Drugs Market Value (US$ Mn) Analysis by Product Type, 2016-2032

Figure 53: Europe Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Product Type, 2022-2032

Figure 54: Europe Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Product Type, 2022-2032

Figure 55: Europe Anti-Viral Drugs Market Value (US$ Mn) Analysis by End User, 2016-2032

Figure 56: Europe Anti-Viral Drugs Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 57: Europe Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 58: Europe Anti-Viral Drugs Market Attractiveness by Product Type, 2022-2032

Figure 59: Europe Anti-Viral Drugs Market Attractiveness by End User, 2022-2032

Figure 60: Europe Anti-Viral Drugs Market Attractiveness by Country, 2022-2032

Figure 61: Asia Pacific Anti-Viral Drugs Market Value (US$ Mn) by Product Type, 2022-2032

Figure 62: Asia Pacific Anti-Viral Drugs Market Value (US$ Mn) by End User, 2022-2032

Figure 63: Asia Pacific Anti-Viral Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 64: Asia Pacific Anti-Viral Drugs Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 65: Asia Pacific Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 66: Asia Pacific Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 67: Asia Pacific Anti-Viral Drugs Market Value (US$ Mn) Analysis by Product Type, 2016-2032

Figure 68: Asia Pacific Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Product Type, 2022-2032

Figure 69: Asia Pacific Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Product Type, 2022-2032

Figure 70: Asia Pacific Anti-Viral Drugs Market Value (US$ Mn) Analysis by End User, 2016-2032

Figure 71: Asia Pacific Anti-Viral Drugs Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 72: Asia Pacific Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 73: Asia Pacific Anti-Viral Drugs Market Attractiveness by Product Type, 2022-2032

Figure 74: Asia Pacific Anti-Viral Drugs Market Attractiveness by End User, 2022-2032

Figure 75: Asia Pacific Anti-Viral Drugs Market Attractiveness by Country, 2022-2032

Figure 76: MEA Anti-Viral Drugs Market Value (US$ Mn) by Product Type, 2022-2032

Figure 77: MEA Anti-Viral Drugs Market Value (US$ Mn) by End User, 2022-2032

Figure 78: MEA Anti-Viral Drugs Market Value (US$ Mn) by Country, 2022-2032

Figure 79: MEA Anti-Viral Drugs Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 80: MEA Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 81: MEA Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 82: MEA Anti-Viral Drugs Market Value (US$ Mn) Analysis by Product Type, 2016-2032

Figure 83: MEA Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Product Type, 2022-2032

Figure 84: MEA Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Product Type, 2022-2032

Figure 85: MEA Anti-Viral Drugs Market Value (US$ Mn) Analysis by End User, 2016-2032

Figure 86: MEA Anti-Viral Drugs Market Value Share (%) and BPS Analysis by End User, 2022-2032

Figure 87: MEA Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by End User, 2022-2032

Figure 88: MEA Anti-Viral Drugs Market Attractiveness by Product Type, 2022-2032

Figure 89: MEA Anti-Viral Drugs Market Attractiveness by End User, 2022-2032

Figure 90: MEA Anti-Viral Drugs Market Attractiveness by Country, 2022-2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Covid-19 Diagnostics Market

Published : August 2020

Healthcare

Influenza Antiviral Market

Published : July 2018

Healthcare

Direct-acting Antiviral Medicines Market

Published : April 2018

Healthcare

Antiviral Immunoglobulin Market

Published : July 2017

Google translate

Anti-Viral Drugs Market